← Back to Search

Small Molecule Drug

ARM210 for Ventricular Tachycardia

Phase 2
Recruiting
Led By Michael J Ackerman, MD PhD
Research Sponsored by Armgo Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants have a confirmed genetic diagnosis of CPVT1 and supporting clinical phenotype, including residual ventricular ectopy on a stable standard-of-care, CPVT1-directed treatment regimen
Is a woman of non-childbearing potential
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is testing a new drug, S48168 (ARM210), to see if it is safe and effective in treating Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease causes fatal changes in heart rhythms, leading to sudden death with exercise or excitement. The new drug is designed to repair the leaky channels that cause the disease. If it is effective, it would allow people with CPVT to live normal, active lives.

Who is the study for?
Adults aged 18-65 with a confirmed genetic diagnosis of CPVT1 and related symptoms, who can follow the study plan and are not pregnant or breastfeeding. They must have a BMI ≤ 36 kg/m2, no recent drug abuse, controlled diabetes if present, no significant heart issues in the past five years, and agree to avoid certain medications and blood donations before and during the trial.Check my eligibility
What is being tested?
The trial is testing S48168 (ARM210), which aims to fix leaky calcium channels caused by CPVT1 mutations that lead to dangerous heart rhythms. Participants will either receive this new drug or a placebo without knowing which one they're getting to compare effectiveness.See study design
What are the potential side effects?
While specific side effects for S48168 (ARM210) aren't listed here, common ones for new drugs targeting heart conditions may include dizziness, headache, nausea, potential allergic reactions or changes in blood pressure or heart rhythm.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have CPVT1 with symptoms, even on my current treatment.
Select...
I cannot become pregnant.
Select...
I am between 18 and 65 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The effect of S48168 (ARM210) treatment on the amount and complexity of exercise-• Change in ectopy score from baseline to Day 28 versus placebo (pre-dose Period 1 baseline to Day 28 Period 1 versus Day 28 Period 2
Secondary outcome measures
Incidence of Treatment-Emergent Adverse Events
Other outcome measures
Evaluation of a novel expanded ectopy scale in exercise stress tests which qualifies both the ectopy and the heart rate at which it occurs.
Evaluation of heart rhythm throughout treatment periods
The pharmacokinetics (PK) of a 28-day administration of S48168 (ARM210) in patients
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: S48168 (ARM210) once daily for 28 daysExperimental Treatment1 Intervention
Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
Group II: Matching Placebo once daily for 28 daysPlacebo Group1 Intervention
Oral dose of placebo once daily on top of standard of care regimen for 28 days.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a condition characterized by abnormal heart rhythms triggered by physical activity or stress, often due to mutations in the Ryanodine Receptor (RyR2) calcium release channels. These mutations cause the channels to become 'leaky,' leading to abnormal calcium handling in heart cells, which can precipitate dangerous arrhythmias. Treatments for CPVT aim to stabilize these channels and prevent arrhythmias. Beta-blockers are commonly used to reduce the heart's response to adrenaline, thereby lowering the risk of arrhythmias. Flecainide, an antiarrhythmic drug, can also be used to block abnormal electrical activity. The novel drug S48168 (ARM210) specifically targets and repairs the leaky RyR2 channels, addressing the root cause of CPVT. This mechanism is crucial as it directly corrects the defective calcium handling, potentially offering a more effective and targeted treatment option for CPVT patients.

Find a Location

Who is running the clinical trial?

Armgo Pharma, Inc.Lead Sponsor
1 Previous Clinical Trials
7 Total Patients Enrolled
Food and Drug Administration (FDA)FED
174 Previous Clinical Trials
1,333,672 Total Patients Enrolled
Michael J Ackerman, MD PhDPrincipal InvestigatorMayo Clinic

Media Library

Catecholaminergic Polymorphic Ventricular Tachycardia Clinical Trial 2023: S48168 (ARM210) Highlights & Side Effects. Trial Name: NCT05122975 — Phase 2
S48168 (ARM210) (Small Molecule Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05122975 — Phase 2
~11 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top